Author

Giovanni Diaz

Institution: Genentech

Observed institution: Genentech

ORCID: 0009-0000-9995-4979

Observed ORCID: 0009-0000-9995-4979

OpenAlex ID: A5113007667

Stratification of Multiple Myeloma Patients in the Commpass Study By Single Cell Transcriptomics of Plasma Cells Associates with Clinical Outcome

2023 · Alireza Tafazzol, Xiangnan Guan, et al. · Blood · 2

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

2025 · Meghan Thompson, Anthony Mato, et al. · Blood · 1

Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans

2026 · Heather Fairfield, Catherine R. Marinac, et al. · Cancer Prevention Research

Machine Learning–Based Unsupervised Molecular Subtyping of Malignant Plasma Single-Cell RNA Data Reveals Tumor-Immune Features Linked to Poor Outcomes in Multiple Myeloma

2025 · Katherine Ferguson, Sarthak Satpathy, et al. · Clinical Lymphoma Myeloma & Leukemia

Integrating Microenvironment with Tumor Multi-Omic using Unsupervised Machine Learning to Model Heterogeneity Refines Multiple Myeloma Subtypes and Reveals Immune-Based Clusters with Prognostic Impact

2025 · Habib Hamidi, Alison Park, et al. · Clinical Lymphoma Myeloma & Leukemia

Integrative Analysis of the Tumor and Microenvironment to Model the Molecular Heterogeneity Underlying the Response to Cevostamab in Relapsed/Refractory Multiple Myeloma

2023 · Habib Hamidi, Rin Nakamura, et al. · Blood

OA-50 Pharmacodynamic effects of tiragolumab, as monotherapy and in combos with daratumumab and atezolizumab in patients with R/R MM: biomarker results from a phase 1a/1b trial

2023 · Shannon Ruppert, Giovanni Diaz, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 7

Citation count: 3

H-index: 1

I10-index: